ロード中...
Epigenetic therapy for ovarian cancer: promise and progress
Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades. Early diagnosis improves survival, but unfortunately only 15% of ovarian cancers are diagnosed at an early or localized stage. Most...
保存先:
| 出版年: | Clin Epigenetics |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6334391/ https://ncbi.nlm.nih.gov/pubmed/30646939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-018-0602-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|